01 — At a Glance
The Generics Darling That Became a CDMO Laboratory
- 52-Week High / Low₹1,141 / ₹517
- Q3 FY26 Revenue₹1,778 Cr
- Q3 FY26 PAT₹252 Cr
- Q3 EPS₹4.66
- Annualised EPS (Q3×4)₹18.64
- Book Value₹89.0
- Price to Book11.5x
- OPM (Q3)27.0%
- Debt to Equity0.46x
- 9M FY26 PAT₹610 Cr
Opening Thought: Laurus delivered ₹1,778 crore revenue in Q3 FY26 (+26% YoY), with PAT of ₹252 crore. Generics segment exploded 37% YoY to ₹1,327 crore. CDMO grew >50% YoY on a 9M basis. Operating margin was 27%. And yet, P/E is 65.7x while ROCE lingers at 18.5%. For context, Cipla trades at 22.4x with 22.7% ROCE. This is not a normal pharma valuation. This is a biotech startup wearing a generics suit.
02 — Introduction
Welcome to the Pharmaceutical Multiverse
Laurus Labs was founded in 2005 and spent its first 15 years being a boring, competent API (Active Pharmaceutical Ingredient) and generic formulations company. It made antiretroviral drugs for HIV patients, steroids, and cardiovascular APIs. Boring, steady, profitable. Then around FY22, management decided being profitable was insufficient. They wanted to be transcendent.
Enter: the CDMO (Contract Development and Manufacturing Organisation) pivot. Enter: the biotech dreams. Enter: peptides, ADCs (Antibody-Drug Conjugates), gene therapies, and immersion cooling fluids for data centres. Suddenly, a ₹5,500 crore ARV and generic API company started investing ₹1,000+ crore annually in capex to build facilities for molecules that don’t exist yet.
The stock went from ₹100 in March 2023 to ₹1,026 today — a 10x run in three years. But here’s where it gets spicy: the company is now being valued like a biotech unicorn despite still earning 85% of its revenues from unexciting generics and APIs. And despite burning capex like a startup, management keeps insisting they’re “progressing well.” Welcome to the Laurus Labs masterclass in investor expectations management.
Reality Check: In the Jan 2026 concall, when asked if the new modalities (ADCs, GT) would contribute meaningfully in next 24 months, the CEO flatly said: “We don’t expect any meaningful revenues coming from ADCs… for the next two years.” Translation: you’re paying 65x earnings for hope, not earnings.
03 — Business Model: Portfolio Chaos (Politely)
APIs, Generics, CDMO, Biotech — Pick a Lane and Stay There
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
